1Department of Internal Medicine, Eulji General Hospital, Eulji University School of Medicine, Seoul, Korea.
2Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea.
3Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Korea.
4Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Ulsan College of Medicine, Seoul, Korea.
5Department of Endocrinology and Metabolism, Kyung Hee University Hospital at Gangdong, Kyung Hee University Medical Center, Seoul, Korea.
6Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
7Astellas Pharma Inc., Tokyo, Japan.
8Astellas Korea Inc., Seoul, Korea.
9Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Copyright © 2017 Korean Diabetes Association
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
CONFLICTS OF INTEREST: K.W.M., B.J.K., J.H.L., M.S.K., K.J.A., M.K.L., and B.S.C. have received research funding from Astellas Pharma Inc. S.K. and S.Y. are employees of Astellas Pharma Inc., Tokyo, Japan. H.J.C. is an employee of Astellas Korea Inc., Seoul, Korea. This study was sponsored by Astellas Pharma Inc., Japan. Medical writing and editorial support was funded by Astellas and provided by Hui Hwa Choo, Bao Hui Lee, and Naina Sharma from Research2Trials Clinical Solutions Pte. Ltd.
Values are presented as number (%) or mean±standard deviation. Data shown are for Visit 1 unless otherwise specified.
BMI, body mass index; HbA1c, glycated hemoglobin; NGSP, National Glycohemoglobin Standardization Program; FPG, fasting plasma glucose; FSI, fasting serum insulin; eGFR, estimated glomerular filtration rate.
aFisher exact test, bTwo-sample t-test.
Values are presented as number (%).
TEAE, treatment-emergent adverse event.
aTotal number of events, where patients may have experienced two or more events, bPatients presenting with two or more TEAEs were counted only once, cThe most severe TEAE was counted if the patient presented with two or more TEAEs with varying severity.
Values are presented as mean±standard deviation.
BUN, blood urea nitrogen; Cr, creatinine; RBC, red blood cell; NAG, β-N-acetyl-D-glucosaminidase; AST, aspartate transaminase; ALT, alanine transaminase; LDH, lactate dehydrogenase; ALP, alkaline phosphatase; γ-GTP, γ-glutamyl transpeptidase.
aTwo-sample t-test.
SGLT2 Inhibitors as Add-On Therapy to Metformin for People with Type 2 Diabetes: A Review of Placebo-Controlled Trials in Asian versus Non-Asian Patients